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Abstract
The porcine reproductive and respiratory syndrome virus (PRRSV) is a major threat to swine health worldwide and is
considered the most significant viral disease in the swine industry today. In past years, studies on the entry of the virus into
its host cell have led to the identification of a number of essential virus receptors and entry mediators. However, viral
counterparts for these molecules have remained elusive and this has made rational development of new generation
vaccines impossible. The main objective of this study was to identify the viral counterparts for sialoadhesin, a crucial PRRSV
receptor on macrophages. For this purpose, a soluble form of sialoadhesin was constructed and validated. The soluble
sialoadhesin could bind PRRSV in a sialic acid-dependent manner and could neutralize PRRSV infection of macrophages,
thereby confirming the role of sialoadhesin as an essential PRRSV receptor on macrophages. Although sialic acids are
present on the GP3, GP4 and GP5 envelope glycoproteins, only the M/GP5 glycoprotein complex of PRRSV was identified as a
ligand for sialoadhesin. The interaction was found to be dependent on the sialic acid binding capacity of sialoadhesin and
on the presence of sialic acids on GP5. These findings not only contribute to a better understanding of PRRSV biology, but
the knowledge and tools generated in this study also hold the key to the development of a new generation of PRRSV
vaccines.
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Introduction
At the end of the 1980s, a new syndromewas described affecting pig
herds in North America and Canada [1,2]. This ‘mystery swine
disease’ manifested itself in respiratory problems and reproductive
disorders and was eventually designated Porcine Reproductive and
Respiratory Syndrome (PRRS), reflecting the associated disease
symptoms. The causative agent is a positive sense RNA virus that
groups within the order Nidovirales, family Arteriviridae, and is referred to
as the PRRS virus (PRRSV) [3]. At present, the disease is endemic in
swine-producing countries worldwide, causing enormous production
losses in the swine industry. A study by Neumann et al. assessing the
economic impact of PRRS on swine production in the US reported an
annual loss of approximately 560.32 million US dollars due to this
syndrome [4]. Also, recent studies report on the emergence of highly
pathogenic variants of the virus in Asia causing atypical PRRS or
‘High Fever’ disease [5–7]. Consequently, PRRS is considered to be
the most significant viral disease problem in the swine industry today.
Availability of safe and effective vaccines is essential for PRRSV
control. Currently, there are two types of PRRSV vaccines on the
market: attenuated and inactivated vaccines. However, these have
specific drawbacks concerning safety [8–10] and efficacy [11–15]
and there is a strong demand for a new generation of vaccines. Up
until now, PRRSV vaccine development often has followed the
trial and error approach. As there was a clear gap in the
knowledge of PRRSV ligands that bind to specific receptors, it was
difficult to aim for specific blocking of crucial steps in PRRSV
infection of the porcine macrophage. A fundamental understand-
ing of how PRRSV enters its host cell is crucial to reverse the tide.
The PRRSV virion consists of a nucleocapsid that is surrounded
by a lipid envelope. The capsid structure consists of nucleocapsid
proteins (N) and contains the viral genome: a single, positive RNA
strand of approximately 15 kb [16–21]. In the viral envelope, six
structural proteins are embedded: the small envelope protein E,
the membrane protein M and the glycoproteins GP2, GP3, GP4
and GP5 [21]. However, some North American PRRSV isolates
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do not seem to incorporate GP3 as a structural membrane protein,
in contrast to European and other North American isolates
[21–24]. The major structural proteins M and GP5 have been
shown to form disulfide-linked heterodimers [21,25,26]. The
minor structural proteins GP2, GP3 and GP4 form non-covalent
heterotrimers in the virion and there are indications that also the E
protein may be associated with the minor glycoprotein trimer
[21,23,27–29].
As has been shown for other arteriviruses, PRRSV shows a
marked in vivo tropism for cells of the monocyte/macrophage
lineage: the virus infects specific subsets of porcine macrophages
[30,31]. Primary cultures of alveolar macrophages (PAM) are the
only cells that allow efficient ex vivo virus propagation. In addition,
a limited number of cell lines support in vitro virus replication upon
adaptation of the virus. One such cell line, the African green
monkey kidney cell line MARC-145 [32], has become the most
widely used cell type for PRRS virus production.
Over the past years, various studies have focussed on the entry
of PRRSV into its host cell. These efforts have resulted in the
identification of a number of macrophage molecules involved in
PRRSV entry. As for many other viruses, initial binding of the
virus to its host cell occurs via interactions with heparan sulphate
glycosaminoglycans present on the cell surface [33–35]. The virus
receptor that determines subsequent virus entry and that likely
accounts for the macrophage tropism of PRRSV has been
identified as porcine sialoadhesin (pSn). This macrophage-specific
molecule is a sialic acid-binding immunoglobulin-like lectin (siglec)
that mediates virus attachment and subsequent internalization via
clathrin-mediated endocytosis [36,37]. Virus attachment to this
receptor is dependent on the sialic acid-binding activity of the N-
terminal immunoglobulin-like domain of pSn [38] and on the
presence of sialic acids on the virion surface [39]. A study by
Delputte et al. pointed out that a2-3 linked sialic acids and to a
lesser extent a2-6 linked sialic acids, most likely present on
complex N-linked glycans attached to viral envelope glycoproteins,
are involved in this interaction [39]. Clearly, a glycosylated
PRRSV protein is responsible for PRRSV binding to pSn, but the
exact viral ligand has not yet been identified. After pSn-dependent
internalization into the endosomal compartment of the macro-
phage, the viral genome is released into the cytoplasm, thereby
initiating the transcriptional and translational events necessary for
the production of new virions. The scavenger receptor CD163 has
been shown to be essential for virus uncoating [40,41]. A pH drop
within the endosome is required [37,42] and also the aspartic
protease cathepsin E and a yet unidentified trypsin-like serine
protease [43] have been implicated in this process.
Although pSn has been shown to be a critical entry receptor for
PRRSV on macrophages, viral envelope glycoproteins that act as
ligands for this receptor have remained elusive. In the light of
vaccine development, knowledge on this is particularly interesting,
since it allows targeting of the immune response to a specific,
critical step in virus infection. Vaccination with a functional viral
pSn-binding epitope can elicit a protective immune response that
specifically blocks the crucial, pSn-dependent internalization of the
virus into its host cell. By construction and use of soluble
recombinant porcine sialoadhesins, we identified the viral M/GP5
glycoprotein complex as a ligand for pSn and showed the sialic
acid-dependency of the pSn-M/GP5 interaction.
Materials and Methods
Ethics statement
The experimental procedure for the collection of porcine alveolar
macrophages was authorized and supervised by the Ethical and
Animal Welfare Committee of the Faculty of Veterinary Medicine
of Ghent University. The use of human red blood cells was
approved by the Medical Ethical Committee of the Ghent
University Hospital and informed written consent was obtained
from the donors of red blood cells.
Monoclonal antibodies
Detection of pSn was performed using the mouse monoclonal
antibody (mAb) 41D3 [36,44] that recognizes a conformational
epitope within the N-terminal sialic acid-binding domain of pSn.
Detection of structural PRRSV proteins was performed using the
following mAbs: mAb VII2D/5-1D (IgG1), mAb XVI11C/5-10F
(IgG2a) and mAb VII2H/2-4D (IgG1) [45] were used for the
detection of GP3, GP4 and GP5, respectively. Detection of the M
protein was performed using mAb 126.3 (IgG2a) [28] and mAb
P3/27 (IgG1) [46] was used for detection of the N protein. MAb
13D12 [47] and mAb 16G12 [48] were used as isotype-matched,
irrelevant control mAbs for the mAbs with IgG1 and IgG2a
isotype, respectively.
Cells and viruses
Porcine alveolar macrophages (PAM) were obtained from 4- to
6-week-old conventional Belgian Landrace pigs from a PRRSV-
negative herd as described by Wensvoort et al. [2] and cultivated as
described by Van Gorp et al. [40]. MARC-145 cells were
cultivated as described before [40]. HEK-293T cells were grown
in DMEM (Gibco) containing 10% heat-inactivated FBS (Gibco),
2 mM L-glutamine, 1 mM sodium pyruvate and a mixture of
antibiotics. Cell cultures were kept in a humidified 5% CO2
atmosphere at 37uC.
Human red blood cells (RBCs) were obtained from healthy
donors and stored at 4uC in Alsever’s solution for up to 7 days.
The European prototype PRRSV strain Lelystad Virus [2] (LV;
kindly provided by G. Wensvoort) was passaged 14 times on
macrophages (macrophage-grown LV stock) or 13 times on
macrophages and subsequently 5 times on MARC-145 cells
(MARC-145-grown LV stock). Virus was semipurified from
the supernatants via ultracentrifugation as described before [39].
Author Summary
The porcine reproductive and respiratory syndrome virus
(PRRSV) is a major threat to swine health worldwide. The
virus specifically targets subpopulations of macrophages,
central players in the immune system, and can persist in
animals for extended periods of time due to a hampered
immunity. At present, no vaccines are available that are
both safe and effective and it is clear that a more rational
vaccine design is needed to solve this problem. Therefore,
advancing our fundamental understanding of PRRSV
biology is crucial. The macrophage-specific lectin siaload-
hesin is a crucial viral receptor on macrophages and
although its role in PRRSV infection is well documented,
its viral counterparts have remained unknown. Using a
soluble form of sialoadhesin, we identified the M/GP5
glycoprotein complex of PRRSV as the ligand for sialoadhe-
sin and found this ligand-receptor interaction to be critically
dependent on the lectin activity of sialoadhesin and on sialic
acids on the GP5 glycoprotein. These data represent a major
breakthrough in the understanding of the role of PRRSV
proteins in viral entry and pave the way for the
development of a new generation of PRRSV vaccines
capable of inducing an immunity that specifically blocks
the interaction between viral M/GP5 and sialoadhesin.
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Virus titrations on MARC-145 cells and macrophages and
calculation of the virus titers were performed as described by
Van Gorp et al. [40].
Construction, production and purification of pSn-Fc
fusion proteins
The pSn cDNA had been cloned previously into the
pcDNA3.1/D vector (Invitrogen) [36]. The soluble Fc-tagged
pSn, pSn4D-Fc, was generated by polymerase chain reaction
(PCR) amplification as done before for human sialoadhesin [49]
and cloning into a modified version of the pEE14 vector,
designated pEE14-3C-Fc [50]. The cDNA fragment correspond-
ing to the first 4 N-terminal immunoglobulin-like domains of pSn
was amplified using forward primer 59-CCTTCACCATG-
GACTTCCTG-39 and reverse primer 59-ACTAGATCTACT-
TACCTGTGCTGACCACCACGCTGACAG-39. The pEE14-
3C-Fc vector was cut with HindIII, treated with Klenow DNA
polymerase to obtain blunt ends and subsequently cut with
BamHI. The PCR product was digested with BglII and cloned
into the cut pEE14-3C-Fc vector, yielding pEE14-pSn4D-3C-Fc.
To obtain a non-sialic acid-binding pSn4D-Fc protein, a point-
mutation (R116E) was introduced in the sialic acid-binding domain
in pEE14-pSn4D-3C-Fc using the Quickchange site directed
mutagenesis kit (Stratagene) with forward primer 59-TCGGG-
CTCCTATAACTTCgaaTTTGAGATCAGCGAGGGC-39 and
reverse primer 59-GCCCTCGCTGATCTCAAAttcGAAGTTA-
TAGGAGCCCGA-39, resulting in pEE14-pSn4DRE-3C-Fc.
For production of the pSn-Fc chimeras, HEK-293T cells were
transiently transfected using calcium phosphate. Transfected cells
were cultured for 3 days in DMEM supplemented with 3% IgG-
depleted low IgG FBS (Gibco), 2 mM L-glutamine, 1 mM sodium
pyruvate, 1% nonessential amino acids (1006 stock; Gibco) and a
mixture of antibiotics in a humidified 5% CO2 atmosphere at
37uC, after which the culture supernatant was collected. The pSn-
Fc fusion proteins were purified from the supernatant using
standard protein A sepharose chromatography following the
manufacturer’s instructions (GE Healthcare). Fractions of the
eluate containing the purified protein were pooled and the buffer
was exchanged to phosphate-buffered saline (PBS) by dialysis.
Purified protein was stored at 270uC until use.
Solid phase red blood cell binding assay
Each well of an Immulon 4HBX 96-well flat-bottomed
microtiter plate (Dynax Technologies Inc.) was coated with
50 ml of 8 mg/ml goat anti-human IgG (Fc- specific; Sigma-
Aldrich Corp.) in 0.05 M carbonate-bicarbonate buffer (pH 9.6;
Sigma-Aldrich Corp.). Plates were washed with PBS containing
0.25% bovine serum albumin (PBA), after which 2-fold dilution
series of the purified siglec-Fc chimera were added to the wells and
incubated for 2 h at ambient temperature. Unbound siglec-Fc
protein was removed by washing with PBA. RBCs were washed
twice in PBA and resuspended in PBA at 0.25% (v/v) immediately
before use. 100 ml of the RBC suspension was added to each well
and the plate was incubated for 30 min at 37uC. The wells were
gently washed with PBA to remove unbound RBCs and RBC
binding was evaluated using an Olympus CK40-F200 inverted
light microscope (Opelco). To quantify RBC binding, the plate
was dried, fixed with methanol and dried again, after which a
peroxidase substrate assay was performed (Substrate Reagent
Pack; R&D Systems; processed according to manufacturer’s
instructions). The result was evaluated measuring the optical
density at 450 nm (OD450) using a Multiskan RC (Thermo
Labsystems). As a positive control, an identical assay was
performed in parallel for mSiglecE-Fc [51], a protein with
established sialic acid-binding activity. As a control for sialic
acid-dependent binding, sialidase-treated RBCs were used. To
remove sialic acids from the cell surface, RBCs were diluted
(0.25% v/v) in RPMI-1640 containing 50 mU/ml Vibrio cholerae
sialidase (Roche Applied Science; specific for a2-3, 6, 8 linked
sialic acids) and incubated for 1 h at 37uC. The RBCs were
subsequently washed with PBA to remove the enzyme, resus-
pended in PBA at 0.25% (v/v) and used in the solid phase binding
assay as described.
SDS-PAGE, Coomassie Blue staining and Western Blot
analysis of pSn-Fc proteins
Samples of purified pSn-Fc protein were mixed with (non-)
reducing Laemmli buffer, boiled for 5 min and subjected to SDS-
PAGE (8% gel) using a BioRad Mini Protean 3 system. For
Coomassie Blue staining, the SDS-PAGE gel was incubated
successively in Coomassie Blue staining solution (0.125% Coo-
massie Blue, 50% methanol, 10% acetic acid), destaining solution I
(50% methanol, 10% acetic acid) and destaining solution II (5%
methanol, 7% acetic acid). Alternatively, for Western Blot analysis,
proteins were transferred from the SDS-PAGE gel to a PVDF
membrane (Membrane Hybond-P, GE Healthcare) via Western
Blotting (BioRad Mini Trans Blot). The membrane was blocked
overnight in PBS +0.1% Tween 20+5% skimmed milk. Detection
of pSn-Fc protein was performed by subsequent incubation of the
blot with the pSn-specific mAb 41D3 and peroxidase-labeled
polyclonal goat anti-mouse antibodies (Dako), followed by
visualization using enhanced chemiluminiscence (ECL; GE
Healthcare). Alternatively, pSn-Fc protein was detected using
peroxidase-labeled goat anti-human IgG antibodies (Fc-specific;
Sigma-Aldrich Corp.) and subsequent ECL.
Analysis of intracellular processing of pSn-Fc proteins
Samples of purified pSn4D-Fc and pSn4DRE-Fc protein were
either left untreated or were treated with endoglycosidase H or
PNGase F (New England Biolabs Inc.; used according to
manufacturer’s instructions). Also, samples of both proteins were
incubated with 100 mU/ml Vibrio cholerae sialidase (Roche Applied
Science; used according to manufacturer’s instructions) for 3 h at
37uC. After addition of reducing Laemmli buffer, samples were
boiled for 5 min and analyzed via SDS-PAGE and Western
Blot using peroxidase-labeled goat anti-human IgG antibodies as
described above.
Evaluation of the PRRSV-binding capacity of pSn4D-Fc
via precipitation experiments
100 ml of Dynabeads protein A (Invitrogen) were coated with
25 mg of pSn4D-Fc protein and incubated with semipurified,
MARC-145-grown PRRSV LV at 37uC. After 90 min of
incubation, the unbound virus fraction was collected, beads were
washed 4 times with PBS and boundmaterial was eluted with 0.1 M
citrate buffer (pH 3.1). Samples of the semipurified virus, the bound
and the unbound fraction were mixed with non-reducing Laemmli
buffer, boiled for 5 min and resolved on a 12% SDS-PAGE gel.
Subsequently, resolved proteins were transferred to a PVDF
membrane via Western Blotting. The membrane was blocked
overnight in PBS +0.1% Tween 20+5% skimmed milk and probed
with a nucleocapsid-specific, a GP5-specific or an isotype-matched
irrelevant control mAb in combination with peroxidase-labeled
polyclonal goat anti-mouse antibodies. The detected protein bands
were visualized using ECL. To confirm that the beads were
efficiently coated with pSn-Fc protein, a sample of the bound
fraction was subjected to SDS-PAGE and Western Blot analysis
Sialoadhesin Binds PRRSV M/GP5
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using the pSn-specific mAb 41D3. As a control, identical
experiments were performed using uncoated beads and beads
coated with the non-sialic acid-binding mutant pSn4DRE-Fc.
Evaluation of the PRRSV-binding capacity of pSn4D-Fc
via infection-inhibition experiments
PAM were seeded at a concentration of 105 cells/well in 96-well
plates and kept in culture for 48 h. 50 ml of a 3-fold dilution series
of pSn4D-Fc or pSn4DRE-Fc (starting concentration 50 mg/ml)
was mixed with a constant amount of virus (5 ml of a 26105
TCID50/ml virus suspension) and incubated for 1 h at 37uC to
allow binding. The mixtures were transferred to the PAM and cells
were incubated for 1 h at 37uC. Soluble receptor-virus mixtures
were then removed, fresh medium was added and cells were
further incubated for 9 h at 37uC, after which they were fixed.
Infected cells were then visualized via a nucleocapsid-specific
immunoperoxidase staining [2] and counted.
Identification of pSn-binding PRRSV proteins and
characterization of pSn-ligand interaction using
pSn4D-Fc
Viral proteins were solubilized from semipurified MARC-145-
grown PRRSV LV by a 1 h incubation in TNE buffer (50 mM
Tris-HCl (pH 7.4), 200 mM NaCl, 1 mM EDTA) containing 1%
NP-40 (Roche Applied Science) and insoluble material was
pelleted by centrifugation at 10,0006g for 45 min. Subsequently,
the virus lysate was incubated with pSn4D-Fc-coated beads. The
precipitation experiment, sample preparation and subsequent
SDS-PAGE and Western Blotting were performed as described
above. Membranes were blocked overnight in PBS +0.1% Tween
20+5% skimmed milk and probed with mAbs directed against the
structural proteins of PRRSV LV and isotype-matched irrelevant
control mAbs in combination with peroxidase-labeled polyclonal
goat anti-mouse antibodies. Detected protein bands were visual-
ized using ECL. Coating of the beads with pSn-Fc protein was
checked as described above. To assess the sialic acid-dependency
of the interaction, an identical experiment was performed using
the non-sialic acid-binding mutant pSn4DRE-Fc. Alternatively,
sialidase-treated virus was used in the precipitations. Semi-purified
virus was incubated with 100 mU/ml sialidase from Vibrio cholerae
in RPMI-1640 for 3 h at 37uC. In parallel, virus was incubated
with the buffer in which the sialidase was supplied. Titration on
alveolar macrophages revealed a 90% decrease in infectivity of
sialidase-treated virus when compared to control-treated virus,
indicating that sialidase treatment removed sialic acids implicated
in viral entry. To evaluate the effect of the treatment on different
envelope glycoproteins, samples of sialidase- and control-treated
virus were subjected to SDS-PAGE and Western Blot analysis
using specific mAbs. The remaining virus was lysed and subjected
to immunoprecipitation using pSn4D-Fc as described above.
Similar precipitation reactions were performed using macro-
phage-grown virus. Lysates of semipurified macrophage-grown
virus were applied to pSn4D-Fc- and pSn4DRE-Fc-coated beads.
The bound and unbound fractions as well as the original virus
lysates were analyzed via SDS-PAGE and Western Blotting as
described above.
Accession numbers
GenBank accession numbers (http://www.ncbi.nlm.nih.gov/
Genbank):
N PRRSV Lelystad virus, complete genome (coding sequence):
M96262
N PRRSV Lelystad virus, individual structural proteins (protein):
AAA46275 (GP2); AAA46276 (GP3); AAA46277 (GP4);
AAA46278 (GP5); AAA46279 (M); AAA46280 (N); P0C6Y6 (E)
N Porcine sialoadhesin: AF509585 (mRNA, complete cds),
AAP47136 (protein)
N Porcine CD163: EU016226 (mRNA, complete cds),
ABV80230 (protein)
N Murine siglec E: AY371487 (mRNA, complete cds),
AAQ72479 (protein)
Results
Construction and structural characterization of pSn-Fc
chimeras
To identify the PRRSV envelope glycoproteins interacting with
pSn, we constructed a soluble form of the pSn receptor (pSn4D-
Fc). This recombinant protein consists of the 4 N-terminal
domains of pSn, coupled with the Fc- and hinge region of human
IgG1 and allows study of PRRSV-pSn interactions in a cell-free
context. The sialic acid-binding activity of pSn has been shown
before to be essential for PRRSV binding [38]. Therefore, a non-
sialic acid-binding mutant of the soluble pSn (pSn4DRE-Fc) was
generated as a control. This protein was obtained by changing the
amino acid R116, which is essential for sialic acid binding, to an E
residue. PSn- and Fc-specific immunofluorescence cell stainings
(Protocol S1) and ELISAs of the cell supernatants (Protocol S2)
revealed that the pSn-Fc chimeras were expressed in transfected
HEK-293T cells and that they were secreted into the culture
medium (data not shown).
After optimization of production and purification, all further
tests and experiments were performed using purified pSn-Fc
proteins. To check the purity of the proteins, samples were
resolved on SDS-PAGE under reducing and non-reducing
conditions and Coomassie Blue staining was performed (Fig. 1A).
Under non-reducing conditions, a single band of more than
250 kDa was seen for both the pSn4D-Fc and pSn4DRE-Fc
protein. Presence of a reducing agent resulted in single bands at
about 80 kDa. These results indicate that the purified pSn-Fc
proteins are present as disulfide-linked dimers under non-reducing
conditions. The fact that single bands were obtained under each
condition shows that the bulk of the protein in the purified
fractions was pSn-Fc protein.
Purified proteins were also subjected to SDS-PAGE and Western
Blot analysis (Fig. 1B). Under non-reducing conditions, both
pSn4D-Fc and pSn4DRE-Fc were recognized by pSn-specific
mAb 41D3. When SDS-PAGE was performed in the presence of
a reducing agent, binding of mAb 41D3 to the blotted proteins was
lost, which is in line with earlier observations for wild type pSn. Both
the pSn4D-Fc and the pSn4DRE-Fc proteins could be detected on
the blot membrane using polyclonal antibodies specific for the Fc-
part of human IgG. Using the Fc-specific polyclonal antibodies for
detection, additional bands could be observed with varying intensity
in between batches. These bands most likely represent pSn-Fc
protein that is partially degraded. Nevertheless, Coomassie Blue
analysis of the same samples clearly indicated that the bulk of the
protein was present in one specific band, which correlates with
conformationally correct pSn-Fc protein.
Wild type pSn undergoes processing in the endoplasmic
reticulum (ER) and Golgi before being displayed at the cell
membrane. During its passage through these compartments, the
protein does not only obtain intramolecular disulfide bridges, but
also N-linked glycans, which are often essential for proper protein
folding. To check intracellular processing of the recombinant
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proteins, purified pSn4D-Fc and pSn4DRE-Fc proteins were
treated with different glycosidases and analyzed via reducing
SDS-PAGE and Western Blotting (Fig. 1C). Treatment of the
proteins with N-glycosidase F, which removes all types of N-linked
glycans, resulted in a clear shift in the protein size. Treatment with
endoglycosidase H, which removes high mannose and some
hybrid types of N-linked carbohydrates from glycoproteins, or
Vibrio cholerae sialidase, removing sialic acids in a a2-3, a2-6 or a2-8
configuration, did not increase the electrophoretic mobility of the
proteins. These results indicate that the soluble pSn proteins carry
mainly complex type N-glycans capped with little or no sialic
acids. The presence of these sugar moieties shows that the soluble
sialoadhesins pass through the ER and Golgi for processing, as has
been shown for wild type pSn [36].
Functional characterization of pSn-Fc chimeras
Since the sialic acid-binding activity of pSn is essential for
PRRSV binding, we first evaluated the sialic acid-binding capacity
of the purified pSn4D-Fc protein. This was done via a solid phase
red blood cell binding assay, a test routinely used to analyze the
sialic acid-binding capacity of sialoadhesin-Fc and other siglec-Fc
chimeras [52] (Fig. 2A & 2B). The pSn4D-Fc protein showed
clear, sialic acid-dependent RBC binding, since removal of sialic
acids from the RBC surface impeded the interaction. The
pSn4DRE-Fc protein did not show RBC-binding activity. These
results indicate that pSn4D-Fc has the capacity to bind sialic acids.
As for full length pSn, the sialic acid-binding activity is critically
dependent on the R116 residue within the N-terminal domain of
pSn.
To assess the PRRSV-binding capacity, pSn4D-Fc was coated
on protein A beads and incubated with purified virus at 37uC to
allow binding. The unbound fraction was then collected, beads
were washed and the bound material was eluted from the beads.
Samples of the bound and unbound fraction and samples of
purified virus were then subjected to non-reducing SDS-PAGE
and Western Blotting and analyzed for the presence of virus using
Figure 1. Structural characterization of pSn-Fc proteins. (A) Samples of purified pSn4D-Fc and pSn4DRE-Fc proteins were subjected to non-
reducing and reducing SDS-PAGE, after which Coomassie Blue staining was performed. (B) (Non-)reducing SDS-PAGE and Western Blot analysis of
purified pSn4D-Fc and pSn4DRE-Fc proteins using Fc-specific antibodies and pSn-specific mAb 41D3. (C) pSn4D-Fc and pSn4DRE-Fc proteins were
treated with specific glycosidases or control treated and subjected to reducing SDS-PAGE and Western Blot analysis using Fc-specific antibodies.
doi:10.1371/journal.ppat.1000730.g001
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mAbs recognizing the GP5 envelope glycoprotein and the
nucleocapsid protein N (Fig. 2C). GP5 and N could clearly be
detected in both the purified virus stock and the bound fraction,
while little or no protein was found in the unbound fraction. These
results show that pSn4D-Fc is able to efficiently bind the virus.
When beads were coated with pSn4DRE-Fc or when uncoated
beads were used, viral proteins were detected in the unbound
fraction but not in the bound fraction. These findings show that
the interaction of pSn4D-Fc with PRRSV is similar to the
interaction between wild type pSn and the virus. To further
substantiate this, we tested the soluble receptors for their infection-
inhibition capacity (Fig. 2D). We found that PRRSV infection of
alveolar macrophages could be partially blocked by pre-incubating
the virus with pSn4D-Fc. This effect was dose-dependent and no
Figure 2. Evaluation of the functionality of pSn4D-Fc as a sialic acid-binding (A & B) and PRRSV-binding (C & D) protein. Qualitative
(A) and quantitative (B) analysis of sialic acid-binding activity using a solid phase red blood cell binding assay. ELISA plates were coated with dilution
series of pSn4D-Fc, pSn4DRE-Fc or mSiglecE-Fc protein, after which human RBCs were added and RBC binding was evaluated. pSn4D-Fc + RBCs (black
square); pSn4D-Fc + sialidase-treated RBCs (white square); mSiglecE-Fc + RBCs (black diamond); mSiglecE-Fc + sialidase-treated RBCs (white
diamond); pSn4DRE-Fc + RBCs (black circle). Values represent means6SEM of 3 experiments. (C) Evaluation of PRRSV-binding activity via
immunoprecipitation experiments. Protein A beads were either coated with the pSn4D-Fc or pSn4DRE-Fc protein or not coated and incubated with
MARC-145-grown PRRSV at 37uC to allow binding. The bound and unbound fractions were collected and subjected to non-reducing SDS-PAGE and
Western Blot analysis using PRRSV N- and GP5-specific mAbs. (D) Evaluation of PRRSV-binding activity via infection-inhibition experiments. A 3-fold
dilution series of pSn-Fc protein was mixed with a constant amount of MARC-145-grown PRRSV, incubated for 1 h at 37uC to allow binding and
transferred to 105 alveolar macrophages. After 1 h of incubation at 37uC, pSn-Fc - virus mixtures were removed, fresh medium was added to the cells
and cells were incubated for 9 h at 37uC, after which they were fixed. Infected cells were then visualized via nucleocapsid-specific immunoperoxidase
staining and counted. pSn4D-Fc (white square); pSn4DRE-Fc (black square). Values represent means6SEM of 3 experiments.
doi:10.1371/journal.ppat.1000730.g002
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such effect was obtained using the pSn4DRE-Fc protein, indicating
that also here the sialic acid-binding functionality of pSn is crucial
for the interaction. These data evidence that the soluble
sialoadhesin pSn4D-Fc can compete with the wild type pSn on
the macrophage surface for specific ligands present on the PRRSV
virion surface and confirm the role of pSn as an important
PRRSV receptor on macrophages.
Identification of pSn-binding PRRSV proteins and
characterization of the pSn-ligand interaction
To identify viral ligands for the PRRSV receptor pSn, pSn4D-
Fc was used in an immunoprecipitation reaction. PSn4D-Fc was
coated on protein A beads and incubated with a lysate of purified
virus at 37uC to allow binding. Subsequently, the unbound lysate
fraction was collected, beads were washed and the bound material
was eluted from the beads. Samples of the bound and unbound
fraction and samples of the original virus lysate were subjected to
non-reducing SDS-PAGE and Western Blotting and analyzed for
the presence of specific viral envelope proteins using protein-
specific mAbs (Fig. 3A). GP3, GP4 and the M/GP5 complex were
all detected in the original virus lysate and in the unbound
fraction. In addition, the M/GP5 complex was detected in the
bound fraction. GP3 and GP4 were however not found in the
bound fraction. These results indicate that the viral M/GP5
complex is able to bind to pSn4D-Fc. Control experiments with
pSn4DRE-Fc pointed out that this protein does not interact with
any of the viral proteins analyzed. This shows that the sialic acid-
binding capacity of pSn is essential for M/GP5 binding and
suggests that sialic acids on GP5 are involved in the interaction
with pSn. Sialidase treatment of PRRSV, which removes sialic
acids from the GP5 protein as indicated by an increased
electrophoretic mobility of the protein on SDS-PAGE (Fig. 3B),
indeed also resulted in loss of M/GP5 binding to pSn4D-Fc
(Fig. 3C).
The experiments described above clearly showed that sialic
acids on the envelope glycoproteins are essential for the pSn-M/
Figure 3. Identification of pSn-binding (glyco)protein(complexe)s of MARC-145-grown PRRSV and characterization of the pSn-
ligand interaction. (A) Protein A beads were coated with the pSn4D-Fc or pSn4DRE-Fc proteins and incubated with a lysate of MARC-145-grown
PRRSV at 37uC to allow binding. The bound and unbound fractions were collected and subjected to non-reducing SDS-PAGE and Western Blot
analysis using virus-specific mAbs. (B) MARC-145-grown PRRSV was either treated with sialidase or control-treated and subjected to reducing SDS-
PAGE and Western Blot analysis using virus-specific mAbs. (C) MARC-145-grown PRRSV was either treated with sialidase or control-treated, lysed and
incubated with pSn4D-Fc-coated protein A beads at 37uC to allow binding. The bound and unbound fractions were collected and subjected to non-
reducing SDS-PAGE and Western Blot analysis using a PRRSV GP5-specific mAb.
doi:10.1371/journal.ppat.1000730.g003
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GP5 interaction. However, as the glycosylation machinery of
MARC-145 cells and porcine macrophages differs, their glycome
and the glycan array present on virus grown in these cells may
differ substantially. As all experiments were performed with
MARC-145-grown virus, immunoprecipitations were also per-
formed using lysates of purified macrophage-grown PRRSV
(Fig. 4). The results showed that also the M/GP5 glycoprotein
complex of macrophage-grown PRRSV binds to the pSn4D-Fc
protein. Binding was also critically dependent on the sialic acid-
binding capacity of pSn, as no interaction was observed with the
non-sialic acid-binding mutant pSn4DRE-Fc. No binding was
observed for the GP3 and GP4 proteins. These results suggest that
macrophage-grown and MARC-145-grown PRRSV interact with
pSn in the same way.
Discussion
PRRSV has a very restricted tropism for subpopulations of
differentiated cells of the monocyte/macrophage lineage. The
virus infects macrophages in lungs and several lymphoid organs,
while other cells such as circulating blood monocytes and
peritoneal macrophages are refractory [53,54]. This restricted cell
tropism has been attributed to the restricted expression pattern of
the PRRSV receptor pSn on these subsets of differentiated
macrophages [36,44,55]. Since pSn is an essential PRRSV-
binding and -internalization receptor on porcine macrophages,
identification of the PRRSV glycoprotein ligands that mediate
virus binding to this receptor is clearly of great importance, not
only for basic understanding of PRRSV replication biology, but
also for development of strategies to tackle PRRSV infection. For
many viruses (e.g. classical swine fever virus, porcine circovirus 2),
subunit vaccines comprising components involved in viral entry
have proven very useful tools in the protection against viral
infection [56–59]. A vaccine capable of inducing antibodies
against the sialoadhesin-binding epitope of PRRSV should be
capable of providing a good protection against PRRSV infection
by neutralizing virus entry. Previously, the interaction of PRRSV
with pSn was shown to be dependent on a functional sialic acid-
binding domain on pSn [38] and on the presence of sialic acids on
the virion [38,39], but the sialic acid-carrying viral ligand was
never identified. This study aimed to identify PRRSV glycoprotein
ligands for the pSn receptor. For this purpose, a soluble pSn was
constructed and characterized. This soluble receptor showed the
same binding functionality as wild type pSn, as it showed sialic
acid-binding activity and could bind PRRSV in a sialic acid-
dependent manner. Via pull-down assays in which the soluble
receptor was mixed with lysates of PRRSV, it was shown that the
M/GP5 complex of the PRRS virus interacts with the pSn
receptor. This interaction was clearly dependent on the sialic acid-
binding capacity of pSn, as a non-sialic acid-binding mutant of the
soluble pSn differing in only one amino acid was not able to bind
M/GP5. Removal of sialic acids from the virus prior to the pull-
down assay also blocked the interaction of the M/GP5 complex
with pSn, evidencing the importance of sialic acids on the GP5
protein for interaction with the receptor. Clearly, the character-
istics of the interaction of M/GP5 with pSn are identical to these of
the interaction of PRRSV particles with pSn, suggesting that the
M/GP5 complex indeed mediates PRRSV-particle binding to
pSn.
In this study, the interaction of PRRSV with the pSn receptor
was initially studied using MARC-145-grown virus, as it is easy to
obtain relatively high virus titers in these cells and it avoids the
necessity of animal sacrifice. Moreover, MARC-145-grown virus
can infect porcine alveolar macrophages and has been shown to
interact efficiently with the pSn receptor [38,40], indicating that
MARC-145 cells provide correct glycosylation for the virus to
interact with pSn. However, the glycome of the primary porcine
macrophage, and hence of the virus grown therein, is most likely
very different from the MARC-145 cell glycome. In the light of
lectin-glycoprotein interaction, it was therefore imperative to
evaluate the interaction of the viral glycoprotein(complexe)s of
macrophage-grown PRRSV with the pSn receptor. Via pull-down
experiments, in which lysates of macrophage-grown PRRSV were
applied to immobilized recombinant sialoadhesins, it was found
that also macrophage-grown PRRSV interacts with pSn via the
M/GP5 glycoprotein complex. The interaction was also critically
dependent on the sialic acid-binding capacity of pSn, indicating
that the interaction of pSn with sialic acids is central to the pSn-
M/GP5 interaction. While it should be kept in mind that primary
Figure 4. Identification of pSn-binding (glyco)protein(com-
plexe)s of macrophage-grown PRRSV. Protein A beads were
coated with the pSn4D-Fc or pSn4DRE-Fc protein and incubated with a
lysate of macrophage-grown PRRSV at 37uC to allow binding. The
bound and unbound fractions were collected and subjected to non-
reducing SDS-PAGE and Western Blot analysis using virus-specific mAbs.
doi:10.1371/journal.ppat.1000730.g004
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macrophages cultured in vitro may also show different glycosylation
than they do in vivo, it is clear that the interaction of pSn with
macrophage-grown virus is more relevant to the in vivo situation
than the interaction with MARC-145-grown virus.
Previous studies on PRRSV have shown that virus glycosylation
is crucial for its infectivity towards macrophages. Treatment of the
virus with N-glycosidase F to remove N-glycans has a negative
impact on viral infectivity and removal of sialic acids from the
virion surface using sialidase even results in a 10- to 20-fold
reduction of the infectivity [39]. Considering the findings of the
present study, these results suggest a central role of sialic acid-
carrying N-glycans on the GP5 glycoprotein in the interaction with
sialoadhesin. The GP5 protein of most PRRSV isolates contains
two conserved N-glycosylation sites. One or more additional
putative N-glycosylation sites can be present, depending on the
virus isolate [25,60,61]. One of the conserved glycosylation sites,
N46 in European isolates, N44 in American isolates, is particularly
interesting in the light of the present study as it appears to be
critical for the formation of infectious PRRSV virions [62,63].
Wissink and coworkers showed that N46 is important for virus
infectivity towards macrophages: the specific infectivity of
recombinant GP5-N
46Q mutant virus, in which the N46
glycosylation site was deleted, was reduced 10- to 20-fold when
compared to the specific infectivity of wild type virus [62]. This
correlates with the reduction in infectivity seen when virus is
treated with sialidase to remove sialic acids from the surface [39].
Together, these data suggest that the critical sialic acid, necessary
for M/GP5 binding to the pSn receptor, is present on the N-glycan
appended to the N46/N44 amino acid. Another interesting
observation is that the N46/N44 residue is part of the primary
neutralization epitope of PRRSV [64–66]. While some other
segments of the GP5 protein appear to be hypervariable, this
epitope is located in an area of the GP5 ectodomain that is highly
conserved among PRRSV isolates [65–70]. This suggests that this
domain has a critical function in virus replication. It has been
suggested to be crucial for the disulfide linkage between GP5 and
M, as the cysteine residue involved in this linkage lies within the
conserved area and since the linkage between GP5 and M is
critical for virion formation [23,26]. It is however also tempting to
speculate that this critical function lies in the interaction of the GP5
glycoprotein with the sialoadhesin receptor, this via essential sialic
acids present on the glycan appended to the N46/N44 residue of
GP5. This could also explain why antibodies directed against this
epitope appear to have a neutralizing effect on infection of
macrophages. Previously, a study by Delputte et al. showed that
neutralizing antibodies can indeed block attachment and inter-
nalization of the virus into macrophages [71].
Sialic acids are acidic monosaccharides often present at the
termini of glycan chains on animal glycoconjugates [72]. Siglecs
like sialoadhesin display a marked preference for specific types of
sialic acids. However, also the linkage of the sialic acid to the
subterminal sugar residue seems to influence the affinity of a siglec
for a specific ligand. In addition, formation of high affinity
interactions can depend on additional structural features of the
glycoconjugate that carries the sialic acid [73]. These factors
contribute to the specificity of a siglec for specific sialylated ligands
and may explain why the GP3 and GP4 envelope proteins,
although they carry sialic acids, do not seem to interact with
sialoadhesin, while the M/GP5 glycoprotein complex shows a
strong binding to this receptor. Furthermore, it is well known that
physiologically relevant, high affinity lectin-glycan interactions
strongly depend on the lectin and glycan valency [74]. As the pSn
receptor is abundantly expressed at the macrophage cell surface
[36] and as a single PRRSV virion carries a whole array of M/
GP5 complexes on its surface [75], it can be expected that also the
interaction between macrophage and virus depends on avidity
rather than on simple affinity.
In conclusion, we identified the M/GP5 complex of PRRSV as
a ligand for the pSn receptor. Furthermore, we showed that the
M/GP5-pSn interaction is critically dependent on the sialic acid-
binding capacity of pSn as well as on sialic acids on the viral GP5
glycoprotein. The information and tools generated in this study
can provide a theoretical and practical basis for the development
and evaluation of a new generation of inactivated and subunit
PRRSV vaccines.
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